Panelists at the BioNTX summit family office discussion included, from left, Timothy Morris of Aacolade Pharma, Vic Stone of Alloy Therapeutics, Justin Yang of GHIC, and Yizhen Dong of Echo Investment Capital. The discussion was moderated by Weaver’s Tyler Ridley. [Photo: BioNTX]
Fundraising has slowed and valuations are down, but biotech founders could have a lifeline in family office investments, panelists at the recent BioNTX summit in Arlington agreed. They said succeeding with these investors can take time, a lot of education, and a compelling, well-crafted story that connects emotionally with the family.